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Background: The role of miRNAs in familial breast cancer (fBC) is poorly investigated as also in the BRCA-like
tumors. To identify a specific miRNA expression pattern which could allow a better fBC classification not only based
on clinico-pathological and immunophenotypical parameters we analyzed miRNA profile in familial and sporadic
samples. Moreover since BRCA1 tumors and sporadic triple negative (TN) breast tumors share similarities regarding
clinical outcomes and some histological characteristics, we focused on TN and not TN cases.
Methods: The sample set included fresh frozen tissue samples, including 39 female fBCs (19 BRCA-related and 20
BRCAX) and 12 male fBC (BRCAX). Moreover, we considered TN and non TN (NTN), 21 BRCA-related and 27 sporadic
BCs. MiRNA profiling was performed through GeneChip miRNA v.1.0 Array (Affymetrix). ANOVA, hierarchical and
consensus clustering analyses allowed identification of pattern of expression of miRNAs and pathway enrichment
analysis, considering validated target genes, was carried out to achieve a deeper biological understanding.
Results: ANOVA test led to the identification of 53 deregulated miRNAs; hierarchical and consensus clustering of
female fBCs (fFBCs) and male fBCs (fMBCs) highlighted the presence of 3 sample clusters named FBC1, FBC2 and
FBC3. We found a correlation between ER-status and the three sample clusters. The three clusters are distinct by
a different expression of two clusters of miRNAs (CLU1 and CLU2), which resulted to be different in targeted
pathways. In particular, CLU1 targets cellular pathways and CLU2 is involved in epigenetic activities. Considering
TN and NTN BRCA-related and sporadic tumors, a hierarchical clustering identified two clusters of miRNAs, which
were not so different from CLU1 and CLU2, both in miRNA content and targeted pathways.
Conclusions: Our results highlighted the importance of miRNA regulation to better clarify similarities and
differences between familial and sporadic BC groups.
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Breast cancer (BC) is a very heterogeneous disease.
Patients with a family history of BC (5-7%) account
for germline mutations in the high susceptibility genes
BRCA1/2 (25%), while 20-25% of fBC can be attributed to
other high-moderate-low susceptibility genes [1]. Moreover
for about the 50% of familial BC (fBC), that show no* Correspondence: s.tommasi@oncologico.bari.it
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unless otherwise stated.mutation in any of these genes, it has been proposed a
polygenic model in which the susceptibility is conferred by
the action of several low-penetrance loci [1]. The genetic
alterations associated with breast carcinogenesis are mostly
studied; on the contrary, epigenetic alterations in fBC is a
new field of interest. The concept of epigenetics refers to
changes in gene activity that does not involve variations in
the primary DNA sequence [2,3]. The most widely studied
class of non coding RNAs are the microRNAs (miRNAs)
[4]. They play an important role in post-transcriptional
gene silencing regulating gene expression by targeting RNA
degradation or translational inhibition through interactiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Danza et al. Journal of Translational Medicine 2014, 12:319 Page 2 of 11
http://www.translational-medicine.com/content/12/1/319with the 3′ untranslated region (UTR) of the target mRNA.
Although there are several reports on the miRNA
expression profile in BC and in different types of BC [5-8],
results are often controversial, leaving the question open
as to whether miRNA profiling can be used or not to
differentiate BC patients. Moreover very little has been
reported about the role of the miRNAs in the subgroups
of fBC or in the BRCA-like tumors.
Recently, studying some miRNAs related to BRCA
genes in fBC, we highlighted the involvement of miR-17,
miR-21, let-7a in familial compared to sporadic BC and
further their higher expression associated with BRCA1/2
mutations [9].
Tanic et al. identified a 17 miRNA signature in fBC
when comparing to normal breast tissue showing that
many of the deregulated miRNAs were involved in the
MAPK signaling pathway in both familial and sporadic
tumors [10]. However, Tanic et al. further explored the
tumor heterogeneity of BC patients without BRCA1 and
BRCA2 mutations (BRCAX patients). They highlighted four
different subgroups (BRCAX-A, −B, −C and -D), character-
ized by 3 specific miRNA clusters and histopathological
features [11].
Recently, 15 miRNAs, able to differentiate among the
four groups (BRCA1, BRCA2, sporadic BC and BRCAX),
have been identified [12]. Each group was composed by
5 BC cases. The first three groups were associated with
distinct clusters of hyper-expressed miRNAs compared to
BRCAX where all these miRNAs were hypo-expressed.
They also found specific miRNAs associated with ER, PR,
and HER2/neu status, Ki 67 and phenotype [12].
However few data are still available on miRNA expression
associated to different clinico-pathological features in fBCs
and in subgroups of sporadic BCs.
Currently, BC classification and choice of treatment still
depend on immunohistochemical (IHC) analysis of markers
among which ER, PR and HER2 are fundamental to define
Triple Negative BC (TNBC) tumors as ER-, PR- and
HER2-. These last tumors seem to behave as BRCA1-
mutated tumors [13,14]. Among the BRCA1-mutated
breast tumors, the triple negative phenotype represents 70-
80%. In particular, patients under 50 years old and with
BRCA1 germline mutations have morphological features
similar to those described for triple negative tumors.
Studies on the role of miRNAs to stratify TNBC did
not provide clear information. The first study totally
focused on TNBC miRNA profiling was by Cascione et al.
in 2013 [5]. Comparing primary TNBC and normal
tissues, the miRNA profiling revealed 116 deregulated
miRNAs, among which miR-106b, the cluster miR-17/92,
miR-8 family, miR-21 and miR-155 were the most
up-modulated while let-7b, let-7c, miR-126, miR-145
and miR-205 were the most down-modulated [5]. The
miR-200 family is a known negative regulator of theepithelial-mesenchymal transition (EMT), through the
direct targeting of Zeb1/Zeb2 [15]. This miRNA family
appears to be one of the most interesting players in TNBC
biology and it was previously described as up-modulated
in BC where its over-expression was correlated with
lymph node positivity and metastasis. The miR-205 exerts
a clearer tumor-suppressive role. Iorio’s group described
its down-modulation in TNBC, in particular in the claudin-
low subgroup [16]. Besides miR-200 family and miR-205, it
must also mention other tumor suppressor miRNAs
particularly involved in TNBC as miR-203, miR-31,
miR-34a; while TNBC oncomiR are miR-181a/b, miR-146
and miR-146b-5p and miR-182 [16].
In order to identify miRNA expression pattern which
could support BC classification in familial BC, we ana-
lyzed miRNA expression in 51 familial sample patients.
Moreover, to better classify TNBCs we compared miRNA
expression of 21 BRCA carriers and 27 sporadic BC cases.
The two main clusters highlighted by hierarchical analysis
evidenced a driver role of ER in fBC. Furthermore, we
demonstrated that BRCA-related and sporadic TNBC
clustered together supporting the hypothesis of similar
epigenetic regulation in these tumors.
Materials and methods
Sample set
A set of 51 fBC patients (12 male and 39 female cases)
was enrolled through the Genetic Counseling Program
at the IRCCS, Istituto Tumori “Giovanni Paolo II” in
Bari, Italy. Patients signed informed consent giving
permission to use their pathological material. In detail,
familial female BCs (fFBCs) included 19 BRCA-related,
indicating with this term patients carrying germline
deleterious mutations in BRCA1/2 genes, and 20 BRCAX.
The term “BRCAX” is used to indicate those patients with
familial BC carrying no mutation in BRCA1/2 genes.
Familial male BCs (fMBCs) are only BRCAX. BRCA1/2
gene mutational status was evaluated through capillary
sequencing on blood-extracted DNA. The analyses on
TNBC and NTNBC have been performed in 21 BRCA-
related and 27 sporadic BCs. The flowchart of the study is
described in Figure 1.
RNA extraction
RNA was extracted from fresh frozen cancer specimens
containing at least 70% tumor cells and from normal tissues
using the RNeasy Plus Mini Kit (Qiagen, Valencia CA)
according to the manufacturer’s protocol. Concentrations
were estimated with the ND-8000 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE).
Microarray hybridization and data preprocessing
Five hundred ng of RNA of each sample were labelled
by using the 3DNA Array Detection FlashTagTM RNA
Figure 1 Analysis workflow. Features of the sample sets are described.
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and analyzed by the Gene Chip miRNA v. 1.0 Array
(Affymetrix) which contains 46,228 probes comprising
7,815 probe sets and covers 71 organisms including 1100
human miRNAs derived from the Sanger miRBase and
miRNA database v11 (April 15, 2008, http://microrna.
sanger.ac.uk). First, poly (A) tailing was carried out at 37°C
for 15 min in a volume of 15 ml reaction mix, which
contained 1X Reaction Buffer, 1.5 ml MgCl2 [25 mM],
1 ml ATP Mix diluted 1:500 and 1 ml PAP enzyme.
Second, Flash Tag Ligation was performed at room
temperature for 30 min by adding 4 ml of 5X Flash
Tag Ligation Mix Biotin and 2 ml T4 DNA Ligase into the15 ml of reaction mix. To stop the reaction, 2.5 ml of Stop
Solution was added. Each sample were hybridized on the
array, washed and stained with the Affymetrix Fluidics
Station 450 and scanned with the AffymetrixGeneChip
Scanner 3000 7G using the Command Console software
(Affymetrix).Raw data (.CEL files) were normalized through
Robust Multi-array Average (RMA) method to remove
systematic variations. Briefly, RMA corrects raw data
for background using a formula which is based on a normal
distribution and uses a linear model to estimate values
on a log-scale. RMA normalization was performed
using the “affy” package of the Bioconductor suite
(http://www.bioconductor.org/) for the R statistical
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been deposited at the ArrayExpress database under
the accession number E-MTAB-2705.
Differential expression analysis
Normalized values were statistically analyzed with MeV
software v.4.8.1 [17]. Differentially expressed miRNAs
were detected through ANOVA, using 500 permutations.
The unadjusted P-values were corrected for multiple
hypotheses testing using Benjamini and Hochberg false
discovery rate (FDR < 0.05) [18]. Data were considered to
be statistical significant when p < 0.01.
Class discovery methods
Unsupervised average-linkage hierarchical clustering using
Pearson correlation was performed through “Hierarchical
clustering” module of Gene Pattern suite [19]. “Consensus
clustering” module was used for class discovery and
clustering validation. Such an analysis was performed
with KNN means algorithm with 2, 3, 4 and 5 centroids
through 500 resampling iterations.
Gini correlation coefficient has been used to assess the
optimal number of clusters. The Gini correlation coefficient
has been borrowed from economics, sociology, physics,
engineering, and informatics to solve a series of mathematic
problems without having to hypothesize the form of data
distribution [20]. The Gini correlation is more robust on
non-normally distributed data and it is more stable for data
containing outliers, compared with the correlation methods
based on normal distributions. Moreover, it provides higher
accuracy than correlation methods that only use rank
information. “Delta Gini” was introduced to consider the
differences in the inequality of edge weights between two
networks and it was used to validate unsupervised
hierarchical analysis.
Pathway enrichment analysis
Pathway enrichment analysis was performed considering
validated targets for each miRNAs in clusters. Results
were obtained from Tarbase [21], miRtarbase [22] and
miRecords [23]. We used these databases because
they collected experimentally validated miRNA targets
(e.g., reporter assay, western and northern blot, qRT-PCR).
The resulting gene list for each cluster was submitted to
DAVID 6.7 bioinformatic tool [24] in order to identify the
targeted pathway, setting the threshold for FDR to 0.01 and
considering enrichment in Gene Ontology (GO) terms.
Results
Unsupervised hierarchical clustering of familial breast
tumors and ER status
Our sample set included fFBCs (19 BRCA-related and
20 BRCAX), fMBC (12 BRCAX) and sporadic BCs (n = 27)
(Figure 1). The ANOVA test performed among the fourgroups, identified 53 differentially expressed miRNAs
(p < 0.01, FDR < 0.05) (Table 1). Unsupervised hierarch-
ical clustering (Figure 2A) and consensus clustering
(Figure 2B-C) in the fBC subset, including male and
female cases, highlighted the presence of 3 sample
clusters (named FBC1, FBC2, FBC3). In particular, in
Figure 2B it could be observed the variation of Gini
coefficient which stated as the optimal number for
patient clusters as 3 because at this value the greatest
value of ΔGini was reached, indicating the greatest
inequality between them.
FBC1 included BRCA-related fFBCs (34.78%) and
BRCAX fMBCs (52.17%); FBC2 included 61.1% BRCAX
fFBC samples and FBC3 contained an equal number of
BRCA-related and BRCAX fFBCs.
Our question was the identification of relationship
between the results of sample clustering and the
clinico-pathological data (ER, PgR and Her2), which
are still considered the gold standard for diagnosis and
prognosis of breast tumors.
Matching these results with all clinico-pathological
features, a correlation between ER-status and the three
sample clusters have been found. In detail, FBC1
samples are 82.6% ER-positive; FBC2 samples are
mostly ER-negative (66.6%); indeed, FBC3 samples are
ER-positive. The three clusters are distinct by different
expression of two clusters of miRNAs, with a high
correlation coefficient (R2 > 0.55). These clusters are
CLU1 (R2 > 0.64) and CLU2 (R2 > 0.84), which included 17
and 36 miRNAs, respectively (Table 2). In particular,
CLU1 is overexpressed in FBC1 and downregulated in
FBC2. CLU2 showed an opposite behavior than CLU1 in
FBC1 and FBC2. FBC3 has a not so clearly defined pattern
of expression of CLU1 and CLU2 (Figure 2A).
In conclusion, these results seemed to indicate that
familial BCs could be stratified accordingly to the pattern
of expression of CLU1 and CLU2.
Triple negative BCs: BRCA-related and sporadic BC
Triple negative breast tumors (TNBCs) are characterized
by a more aggressive phenotype and include subgroups
with features shared with BRCA-related BCs. For this
reason we explored the pattern of expression of miRNAs in
21 BRCA-related and 27 sporadic BCs, taking into account
TNBC and NTNBC immunophenotype (Figure 1).
Unsupervised hierarchical clustering of BRCA-related
and sporadic BCs evidenced two sample clusters: one of
them [A] included 64.7% sporadic BCs which are triple
positive; interestingly, the second [B] is separated into two
subclusters, as shown in the dendrogram, one of 83.33%
TNBCs and the second of 89.47% NTNBCs, almost
including an equal number of BRCA-related and sporadic
samples (Figure 3). [A] and [B] are characterized by differ-
ent expression of two clusters of miRNAs: SET1 (R2 > 0.75)
Table 1 ANOVA test results from the comparison between male and female familial breast cancer and sporadic tumors
fMBC fFBC
BRCAX BRCA-related BRCAX sporadic P
hsa-miR-106b 9.34 ± 0.57 5.88 ± 2.72 5.09 ± 2.48 5.69 ± 2.63 5.49E-05
hsa-miR-1259 2.15 ± 0.15 2.31 ± 0.15 2.47 ± 0.24 2.27 ± 0.18 8.93E-05
hsa-miR-125a-3p 6.01 ± 1.04 4.11 ± 1.22 3.76 ± 1.21 3.83 ± 1.36 1.00E-05
hsa-miR-1271 3.58 ± 0.81 3.01 ± 0.44 2.62 ± 0.30 2.73 ± 1.36 1.59E-05
hsa-miR-1274a 6.83 ± 1.78 3.73 ± 1.68 2.88 ± 0.98 3.65 ± 1.23 2.99E-10
hsa-miR-1274b 9.44 ± 1.38 5.78 ± 2.48 4.31 ± 2.04 5.69 ± 2.30 1.70E-07
hsa-miR-128 4.32 ± 1.56 2.95 ± 0.74 2.57 ± 0.33 2.80 ± 0.63 4.66E-07
hsa-miR-140-5p 3.13 ± 0.83 2.58 ± 0.46 2.30 ± 0.15 2.36 ± 0.20 1.83E-06
hsa-miR-143-star 4.03 ± 1.43 2.51 ± 0.38 2.53 ± 0.40 2.53 ± 0.42 5.70E-09
hsa-miR-143 10.12 ± 1.36 6.82 ± 2.58 6.08 ± 2.66 6.11 ± 2.87 8.81E-05
hsa-miR-148a 4.45 ± 1.62 2.83 ± 0.57 2.66 ± 0.55 3.11 ± 1.08 9.25E-06
hsa-miR-148b 3.34 ± 0.99 2.50 ± 0.23 2.46 ± 0.26 2.48 ± 0.34 1.53E-06
hsa-miR-152 7.76 ± 1.36 4.82 ± 1.84 4.07 ± 1.82 4.52 ± 1.82 1.11E-06
hsa-miR-15a 6.72 ± 0.87 3.95 ± 1.27 3.20 ± 1.05 3.88 ± 1.41 1.39E-10
hsa-miR-17-star 4.43 ± 0.68 3.12 ± 0.95 2.58 ± 0.44 2.70 ± 0.56 1.73E-10
hsa-miR-181c-star 3.10 ± 0.82 2.43 ± 0.28 2.51 ± 0.31 2.41 ± 0.24 2.69E-05
hsa-miR-188-5p 3.19 ± 0.43 2.55 ± 0.35 2.50 ± 0.32 2.74 ± 0.40 1.46E-05
hsa-miR-192 3.75 ± 0.82 2.56 ± 0.30 2.49 ± 0.40 2.55 ± 0.49 4.51E-10
hsa-miR-193a-3p 5.25 ± 1.22 2.65 ± 0.49 2.75 ± 0.65 2.76 ± 0.53 0
hsa-miR-194 4.98 ± 1.53 3.33 ± 0.94 3.28 ± 1.04 3.09 ± 0.83 1.11E-05
hsa-miR-19a 3.10 ± 0.48 2.58 ± 0.36 2.55 ± 0.26 2.53 ± 0.32 6.38E-05
hsa-miR-19b 7.22 ± 1.16 4.99 ± 1.91 3.66 ± 1.49 4.33 ± 1.80 1.15E-06
hsa-miR-200a-star 4.16 ± 0.89 2.90 ± 0.54 2.75 ± 0.44 2.93 ± 0.45 3.10E-09
hsa-miR-200a 6.75 ± 1.87 4.10 ± 1.47 3.55 ± 1.49 3.68 ± 1.53 6.00E-07
hsa-miR-203 6.09 ± 2.68 3.97 ± 1.76 3.31 ± 1.25 3.26 ± 1.24 2.68E-05
hsa-miR-21-star 5.71 ± 1.41 3.58 ± 1.12 3.19 ± 1.09 3.28 ± 0.99 3.98E-08
hsa-miR-21 7.05 ± 2.00 4.86 ± 1.91 3.67 ± 1.50 4.79 ± 2.04 8.21E-05
hsa-miR-214-star 3.90 ± 1.38 2.62 ± 0.69 2.54 ± 0.47 2.61 ± 0.49 4.32E-06
hsa-miR-22-star 3.12 ± 0.63 2.55 ± 0.24 2.60 ± 0.31 2.49 ± 0.21 8.00E-06
hsa-miR-22 9.86 ± 0.92 6.35 ± 2.64 5.40 ± 2.83 6.34 ± 2.87 1.20E-04
hsa-miR-24-2-star 4.11 ± 1.00 2.96 ± 0.79 2.67 ± 0.42 2.83 ± 0.61 1.13E-06
hsa-miR-27b-star 3.06 ± 0.38 2.49 ± 0.39 2.49 ± 0.33 2.54 ± 0.34 1.00E-04
hsa-miR-29b 3.74 ± 1.31 2.40 ± 0.21 2.42 ± 0.23 2.47 ± 0.38 4.21E-09
hsa-miR-29c-star 3.66 ± 1.08 2.41 ± 0.32 2.33 ± 0.25 2.43 ± 0.27 6.70E-11
hsa-miR-29c 4.27 ± 1.48 2.56 ± 0.35 2.52 ± 0.28 2.55 ± 0.48 9.49E-11
hsa-miR-30b 6.59 ± 1.87 4.25 ± 1.57 3.82 ± 1.47 4.34 ± 1.76 1.44E-04
hsa-miR-30c-2-star 4.27 ± 1.22 3.23 ± 0.99 2.75 ± 0.61 2.98 ± 0.55 1.90E-05
hsa-miR-30e 4.95 ± 1.35 3.23 ± 0.81 2.68 ± 0.43 3.07 ± 0.72 3.36E-10
hsa-miR-3160 2.77 ± 0.41 2.47 ± 0.24 2.32 ± 0.23 2.44 ± 0.20 1.26E-04
hsa-miR-3172 6.25 ± 0.50 3.74 ± 1.34 3.58 ± 1.45 4.15 ± 1.79 1.48E-05
hsa-miR-331-3p 5.18 ± 0.68 3.98 ± 1.24 3.57 ± 1.11 3.49 ± 0.95 8.87E-05
hsa-miR-339-3p 6.00 ± 0.56 4.34 ± 1.39 3.75 ± 1.55 3.97 ± 1.47 1.59E-04
hsa-miR-375 9.66 ± 1.24 5.46 ± 2.70 5.39 ± 2.84 5.14 ± 2.79 2.16E-05
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Table 1 ANOVA test results from the comparison between male and female familial breast cancer and sporadic tumors
(Continued)
hsa-miR-4317 3.40 ± 0.38 2.74 ± 0.35 2.63 ± 0.31 2.61 ± 0.27 2.92E-09
hsa-miR-451 4.65 ± 1.10 3.32 ± 0.81 3.06 ± 0.72 3.47 ± 0.70 6.66E-06
hsa-miR-455-5p 2.99 ± 0.39 2.39 ± 0.27 2.44 ± 0.22 2.46 ± 0.20 6.54E-08
hsa-miR-497 6.92 ± 1.60 3.79 ± 1.46 3.50 ± 1.37 3.86 ± 1.49 2.62E-08
hsa-miR-551b-star 4.99 ± 0.95 4.12 ± 0.91 3.69 ± 0.99 4.96 ± 1.03 5.20E-05
hsa-miR-590-3p 2.04 ± 0.12 2.25 ± 0.15 2.36 ± 0.20 2.28 ± 0.22 1.86E-04
hsa-miR-660 4.29 ± 1.19 3.11 ± 0.46 2.91 ± 0.65 3.19 ± 0.73 1.88E-05
hsa-miR-769-5p 4.38 ± 0.72 2.75 ± 0.46 2.64 ± 0.46 2.67 ± 0.41 7.77E-16
hsa-miR-887 3.92 ± 1.18 2.78 ± 0.55 2.68 ± 0.49 2.85 ± 0.57 9.95E-06
hsa-miR-98 4.35 ± 0.87 3.22 ± 0.69 3.11 ± 0.79 2.98 ± 0.63 6.39E-06
fMBC: familial male breast cancer; fFBC: familial female breast cancer. Data are reported as mean log2[intensity values] ± standard deviation.
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of 18 miRNAs mainly included in CLU1 plus miR-125a-3p
and miR-331-3p, is overexpressed in the cluster including
TN and NTN ([B]). Sample cluster of triple positive
sporadic BCs ([A]) overexpressed SET2, consisting of
21 miRNAs which are a subgroups of CLU2.
GO functional annotation of miRNA clusters
To better understand the biological meaning of the
previously evidenced clusters of miRNAs, we performed a
pathway enrichment analysis. Briefly, databases of experi-
mentally validated targets of miRNAs have been queried
(TarBase, miRtarbase and miRecords) in order to achieve a
“validated” functional understanding.
Pathway enrichment analysis of CLU1 and CLU2
CLU1, which is overexpressed in familial sample cluster
FBC1, indicated an association to GO functional categories
related to “epithelial to mesenchimal transition”, “hypoxia”,
“angiogenesis”, “regulation of cell death”, “cell motility”,
“cell cycle” and, interestingly, to the “response to estrogen
stimulus”. GO functional categories related to CLU2, which
is overexpressed in FBC2, are, in particular, “transcription”,
“regulation of transcription from RNA polymerase II
promoter”, “transcription repressor activity”, “negative
regulation of gene expression”, “methylation“, “histone
acetyltransferase activity” and “lysine N-acetyltransferase
activity” (Table 4).
Such result seems to indicate that CLU1 is responsible
for regulation of cellular pathways and CLU2 is involved
in epigenetic activities.
Pathway enrichment analysis of SET1 and SET2
GO term enrichment analysis of SET1 and SET2 revealed,
as expected, no particular differences compared to results
regarding CLU1 and CLU2. Interestingly, the term “ER
nuclear signaling pathway” merged from the analysis for
SET1, indicating a peculiar role for the estrogen receptor,and the term “histone modification” was found, which
did not merged from the functional annotation analysis
for CLU1.
In conclusion, the analysis did not give us results
different from those of CLU1 and CLU2 because SET1
and SET2 are not so different in their miRNA content.
Discussion
Since miRNAs deregulation was initially described in BC
[25], numerous studies have been focused on the most
differentially expressed miRNAs allowing to a better
knowledge about their biological role in this heterogeneous
disease. Although increasing efforts have been undertaken
to elucidate the potential use of miRNAs as diagnostic and
prognostic tool, the informative power of miRNA profiles
in breast tumor still remains unclear. There is an extensive
number of studies investigating the expression of miRNAs
in breast carcinoma but few data are available when the
focus is restricted to specific breast tumor subgroups such
as familial BCs. Our aim was to identify a specific
miRNA signature in familial BC subgroup according
to clinico-pathological parameters, also considering
the sporadic BC. Until recently, there is a limited number
of reports exploring miRNA profile in familial breast
tumors, which considered only the family history and the
mutational status of BRCA [9-12]. In this regard, this is
the first study evaluating whether there is an epigenetic
regulation able to highlight a specific clinico-pathological
assessment in familial and sporadic breast tumors.
Our hierarchical analysis highlighted two different
clusters, CLU1 and CLU2, consisting of 17 and 36 miRNAs,
respectively. Considering FBC1 and FBC2, CLU1 and
CLU2 were able not only to discriminate ER-negative from
ER-positive breast tumors but also female BRCA-unrelated,
female BRCA-related and male BCs. A key role for the
estrogen receptor alpha (ERα) in the pathogenesis of BC
has been well described. ERα is correlated to survival and
cell proliferation pathways through both genomic and
Figure 2 (See legend on next page.)
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Figure 2 Clustering analysis of familial breast tumors. A) Unsupervised hierarchical clustering of fFBCs (BRCA-related and BRCAX) and FMBCs
over 53 deregulated miRNAs (Pink indicates overexpressed miRNAs; blue indicates underexpressed miRNAs); B) Bootstrap analysis of the sample
set by Consensus Clustering. Plot shows change in Gini correlation coefficient (ΔGn) with each additional group added, indicating that the
optimal numbers of clusters is three; C) Red squares in the consensus matrix represent the subgroup of the sample set. fMBC: familial male breast
cancer; fFBC: familial female breast cancer.
Table 2 MiRNAs belonging to CLU1 and CLU2
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with each other in crosstalk [26]. Our enrichment analysis
highlighted numerous signaling pathways specifically
associated with both CLU1 and CLU2. Among these,
cellular signals such as hypoxic, epithelial to mesenchymal
transition (EMT) and Ras protein signals transduction
involved in the tumor progression were mainly correlated
with CLU1, whereas chromosomal regulation and epigen-
etic mechanisms were found mainly associated with CLU2.
Since an over-expression of CLU1 was observed in female
BRCA-related and male breast tumors expressing ER, we
supposed that ER signaling pathways could be more
involved in the pathogenesis of this BC subgroups. To
support our hypothesis, ER-nuclear signaling pathway and
response to estrogen stimulus were found among the
pathways associated with CLU-1 miRNAs co-expression.
On the contrary, the over-expression of CLU2 in
ER-negative familial subgroup highlighted the potential
role of epigenetic mechanisms in the regulation of ER
expression. A set of microRNAs such as mir-342, mir-299,
mir-217, mir-190, mir-135b and mir-218 were found to be
associated with the estrogen receptor status in breast
tumor samples in which a miRNA signature able to
predict ER, progesterone receptor (PgR) and human
epidermal receptor-2 (HER2) status was highlighted
through an artificial neural network (ANN) analysis
[27]. Recently, the association between miRNAs and
estrogen receptor has been also investigated by numerous
studies exploring the epigenetic role in the endocrine
resistance [28]. Among the mechanisms involved in the
acquisition of a non-responsive phenotype, the post-
transcriptional regulation of ER by miRNAs has been
revealed. In this regard mir-22, mir-206, mir-222, mir-221
and mir-18a have been suggested to target ER, inducing an
estrogen signaling reduction [29]. Among CLU2-signaling
pathways revealed by our enrichment analysis, histone ace-
tyltransferase and a lysine N-acetyltransferase activities were
reported. Interestingly, H3 and H4 histones deacetylation
by HDAC is one of the mechanism described for the ER
promoter activity regulation [30]. Moreover, our analysis
revealed an association of the transcription cofactor activity
with CLU-2 miRNAs coexpression, supporting the hypoth-
esis of an ER transcriptional activity influenced by changes
in coregulatory protein expression levels previously de-
scribed [26]. In fact, a key role for miR-17-5p in ER coacti-
vator SRC-3/AIB1/NCOA3 regulation was reported [31].
Figure 3 Clustering analysis of BRCA1-related and sporadic breast tumors. (Pink indicates overexpressed miRNAs; blue indicates
underexpressed miRNAs).
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subdivided, TNs account for 10%-15% of all BCs. TNBCs
are used to define BC that lacks hormone receptors and
HER2 and they represent the most aggressive subtype with
a poor prognosis [32]. According to Lehmann classification,
TNBCs are subdivided in six different subtypes such asTable 3 MiRNAs belonging to SET1 and SET2 respectively,






















mir-887basal I and II, mesenchymal and mesenchymal stem cell-
like, immunomodulatory and androgen pathway enriched
[33]. Over 80% of hereditary BRCA1-mutated cancers are
TNBCs and the pivotal role played by the inactivation of
BRCA1 in TNBC immunophenotype has been suggested
by several studies investigating the similar clinical out-
comes and histological characteristics between hereditary
BRCA1-related and sporadic TNBC [34]. Stratifying BC in
triple- and non triple negative tumors, two miRNA clusters,
SET-1 and SET-2, were delineated by our hierarchical ana-
lysis. SET-1 included almost all CLU-1 miRNAs with theTable 4 Signaling pathways associated to CLU1 and CLU2
clusters
Signaling pathway P-value Cluster
Regulation of cell death 3.80E-09 CLU1
Cell cycle 7.00E-08 CLU1
ER-nuclear signaling pathway 4.10E-06 CLU1
Angiogenesis 2.00E-04 CLU1
Response to estrogen stimulus 7.30E-04 CLU1
Epithelial to mesenchymal transition 3.40E-03 CLU1
Ras protein signal transduction 9.80E-03 CLU1
Cell motility 1.20E-02 CLU1
Response to hypoxia 1.30E-02 CLU1
Transcription 9.50E-06 CLU2
Regulation of transcription from RNA
polymerase II promoter
1.20E-05 CLU2
Transcription repressor activity 1.30E-05 CLU2
Negative regulation of gene expression 3.70E-05 CLU2
Methylation 2.40E-04 CLU2
Histone acetyltransferase activity 1.60E-03 CLU2
Lysine N-acetyltransferase activity 1.60E-03 CLU2
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http://www.translational-medicine.com/content/12/1/319exception of mir-125a and mir-331, whereas SET-2
consisting of several CLU-2 miRNAs. Different expression
of both SET-1 and SET-2 delineated two groups: SET-1
over-expressing group [B] that included BRCA-related
and sporadic breast tumors with and without TN pheno-
type and SET-2 over-expressing group [A], consisting
mainly of sporadic NTNBCs. Surprisingly, within [B] a
sub-hierarchical cluster able to discriminate TN from
NTN breast tumors was observed. According to miRNA
profile, the characteristic tendency of TNBCs to cluster
differentially compared to other breast tumor groups
expressing ER, PgR or HER2, was reported in a set of
normal, DCIS and invasive BC cases [35]. Furthermore, a
more recent study focused on TNBC and normal tissues
highlighted a profile of 116 deregulated miRNAs, among
which let-7b, let-7c, mir-126, mir-145 and mir-205 were
the most down-modulated and the cluster mir-17/92,
mir-106b, mir-8 family, mir-21 and mir-155 were the
most up-modulated [5]. Interestingly, in our study,
both TNBC and NTNBC subgroups included either
BRCA-related as sporadic breast tumors. BRCA1 is a
tumor suppressor gene that plays a pivotal role in the
maintenance of genomic stability. The presence of
germline mutation in BRCA1 gene and the loss of
protein function increases the risk of BC development
[36]. It has been well-reported that sporadic basal tumors,
show reduced BRCA1 mRNA expression, frequently due
to an epigenetic modification of the BRCA1 gene
[14,37]. In the last years, the concept of ‘BRCAness’
was postulated in order to identify a significant pro-
portion of sporadic BCs with BRCA-like functional
abnormalities and characterized by an analogous
BRCA1 treatment susceptibility [38]. Interestingly our
data, in according to miRNA profile, highlighted a
fraction of NTNBCs, consisting of both BRCA-related
and sporadic breast tumors that clustered with TNBCs.
Differently from [A] group consisting of 88.23% of
sporadic BCs, the fraction of NTNBC belonged to [B]
group, included both sporadic and BRCA-related breast
tumors. However, our data needed of further analysis in
greater BC cohort. Accordingly to literature data, we
found that BRCA-related and sporadic TNBC clustered
together supporting the hypothesis of a similar epigenetic
regulation in these tumors.
Conclusions
Our results highlighted a key role for BRCA1/2 genes
and ER in familial BC pathogenesis. BRCA1 and ER
crosstalk has already been investigated, describing a dual
role for BRCA1 as both co-repressor and co-activator of
ER-mediated transcription [29]. In conclusion, miRNAs
expression pattern in familial and sporadic BCs, related to
immunophenotype, could better clarify similarities and
differences between these two groups.Abbreviations
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